Search details
1.
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.
Blood
; 141(13): 1574-1583, 2023 03 30.
Article
in English
| MEDLINE | ID: mdl-35984902
2.
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Blood
; 141(6): 620-633, 2023 02 09.
Article
in English
| MEDLINE | ID: mdl-36223594
3.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Blood
; 141(14): 1724-1736, 2023 04 06.
Article
in English
| MEDLINE | ID: mdl-36603186
4.
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Blood
; 140(16): 1816-1821, 2022 10 20.
Article
in English
| MEDLINE | ID: mdl-35853156
5.
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Blood
; 140(15): 1674-1685, 2022 10 13.
Article
in English
| MEDLINE | ID: mdl-35960871
6.
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Blood
; 139(13): 2024-2037, 2022 03 31.
Article
in English
| MEDLINE | ID: mdl-34936696
7.
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.
Haematologica
; 109(4): 1082-1094, 2024 Apr 01.
Article
in English
| MEDLINE | ID: mdl-37941406
8.
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
Am J Hematol
; 99(2): 182-192, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37782758
9.
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Br J Haematol
; 201(6): 1129-1143, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36990798
10.
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Blood
; 137(2): 232-237, 2021 01 14.
Article
in English
| MEDLINE | ID: mdl-33443552
11.
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Platelets
; 34(1): 2264940, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37822056
12.
The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer.
Int J Mol Sci
; 23(7)2022 Mar 23.
Article
in English
| MEDLINE | ID: mdl-35408841
13.
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
Blood
; 133(11): 1217-1221, 2019 03 14.
Article
in English
| MEDLINE | ID: mdl-30692124
14.
Differential RNA splicing as a potentially important driver mechanism in multiple myeloma.
Haematologica
; 106(3): 736-745, 2021 03 01.
Article
in English
| MEDLINE | ID: mdl-32079689
15.
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Blood
; 132(6): 587-597, 2018 08 09.
Article
in English
| MEDLINE | ID: mdl-29884741
16.
Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma.
Haematologica
; 105(4): 1055-1066, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31221783
17.
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Blood
; 130(6): 732-741, 2017 08 10.
Article
in English
| MEDLINE | ID: mdl-28588019
18.
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Br J Haematol
; 179(3): 399-409, 2017 Nov.
Article
in English
| MEDLINE | ID: mdl-28771673
19.
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Blood
; 125(26): 4042-51, 2015 Jun 25.
Article
in English
| MEDLINE | ID: mdl-25869284
20.
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Blood
; 126(6): 779-89, 2015 Aug 06.
Article
in English
| MEDLINE | ID: mdl-26002965